Lv3
248 积分 2025-09-09 加入
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
3天前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
3天前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
3天前
已完结
Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: A population-based prospective cohort study of 57,053 men and women in Denmark
1个月前
已完结
Cohort Profile: The Guangzhou Biobank Cohort Study, a Guangzhou–Hong Kong–Birmingham collaboration
1个月前
已完结
Maladaptive emergency granulopoiesis predicts poor outcomes in patients hospitalized with decompensated cirrhosis
7个月前
已完结
Organoid Vascularization: Strategies and Applications
7个月前
已完结
Microfluidic organoids-on-a-chip: The future of human models
7个月前
已完结
Hepatic glycogenesis antagonizes lipogenesis by blocking S1P via UDPG
7个月前
已完结
Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH
7个月前
已完结
皖公网安备34019202002308
